A recent study by scientists in China reveals that the country is developing a drug to treat adverse reactions caused by Covid-19 vaccines.
The study entitled “A drug candidate for the treatment of adverse reactions caused by pathogenic COVID-19 virus-inducible antibodies and vaccines” was published in bioRxiv, an open-access preprint repository for biology, on 18 August.
The researchers noted that in a previous study they found that certain anti-spike proteins from Covid-19 and SARS-CoV viruses “can have a pathogenic effect by binding to lung epithelial cells and misleading immune responses to attack the cells themselves”. They called this pathogenic mechanism “antibody-dependent autoattack (ADAA)”.
Following this, the researchers conducted another study to explore a possible drug candidate to combat ADAA by preventing it altogether or treating ADAA-based diseases.
“The drug candidate is a formulation comprising N-acetylneuraminic acid methyl ester (NANA-Me), an analogue of N-acetylneuraminic acid. NANA-Me acts through a unique mechanism of action (MOA), which is the repair of missing sialic acid in diseased lung epithelial cells.
The scientists noted that this drug candidate has the ability to block antibodies that bind to diseased cells, which are vulnerable to pathogenic antibodies, stating that: “Our in vivo data showed that the formulation significantly reduced disease and deaths caused by pathogenic anti-peak antibodies. Therefore, the formulation has the potential to prevent and treat severe conditions caused by pathogenic antibodies during a COVID-19 infection”.
The study concluded that the drug has the potential to “prevent and treat adverse reactions to Covid-19 vaccines because the vaccines can induce similar antibodies, including pathogenic antibodies”.
While this may seem to some like a potentially valuable treatment for adverse reactions to vaccines, it simply seems as if big pharma has produced yet another drug that could cause injury and side effects, only to join the cycle of drug disease.